ClinicalTrials.gg
Sign In
CompletedNCT06230523Updated Jun 24, 2026Results posted

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

A Phase 2 interventional study of Eloralintide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 43 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 17 visits.

02

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Overnutrition
  • Hormones
  • Chronic weight management
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's enrollment of 263 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,106 studies on the registry; 152 are open to participants now.

Of its 536 completed or terminated interventional studies of FDA-regulated products, 357 (67%) have results posted.

Browse Eli Lilly and Company studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

W8M-MC-LAA1

  • Are males and females who agree to abide by the reproductive and requirements

W8M-MC-CWMM:

  • Have a (BMI)

    • ≥30 kilogram/square meter (kg/m²), or
    • ≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity
  • Have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss.

Exclusion criteria

Exclusion Criteria:

W8M-MC-LAA1

  • Have any prior diagnosis of diabetes mellitus except gestational diabetes.

  • Have any of the following cardiovascular conditions within 6 months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure (CHF).
  • Have a history of acute or chronic pancreatitis.
  • Have an on-going or history of bradyarrhythmia and/or sinus bradycardia at screening and baseline.

W8M-MC-CWMM

  • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
  • Have type 1 diabetes mellitus, latent diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
  • Have poorly controlled hypertension.
  • Have a history of symptomatic gallbladder disease within the past 2 years
  • Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
  • Have a lifetime history of suicide attempts.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
263 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received subcutaneous (SC) injections of eloralintide-matching placebo administered once weekly (QW) for 48 weeks.

    Drug: Placebo

  • Experimental
    1 mg Eloralintide

    Participants received eloralintide 1 milligram (mg) SC QW for 48 weeks.

    Drug: Eloralintide

  • Experimental
    3 mg Eloralintide

    Participants received eloralintide 3 mg SC QW for 48 weeks.

    Drug: Eloralintide

  • Experimental
    6 mg Eloralintide

    Participants received eloralintide 6 mg SC QW for 48 weeks.

    Drug: Eloralintide

  • Experimental
    9 mg Eloralintide

    Participants received eloralintide 9 mg SC QW for 48 weeks.

    Drug: Eloralintide

  • Experimental
    6/9 mg Eloralintide

    Participants received eloralintide 6 mg SC QW for 20 weeks, followed by eloralintide 9 mg SC QW for 28 weeks, for a total treatment duration of 48 weeks.

    Drug: Eloralintide

  • Experimental
    3/6/9 mg Eloralintide

    Participants received eloralintide 3 mg SC QW for 4 weeks, followed by eloralintide 6 mg SC QW for 4 weeks, followed by eloralintide 9 mg SC QW for 40 weeks, for a total treatment duration of 48 weeks.

    Drug: Eloralintide

Interventions

  • DrugEloralintide

    Administered SC.

    Also known as: LY3841136

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 48

    Least squares (LS) means were calculated using a mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Treatment + Time + Sex + Baseline BMI Category + Baseline + Time\*Sex +Time\*Baseline BMI Category + Treatment\*Time + Time\*Baseline. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Change From Baseline in Body Weight at Week 48

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment + Time + Sex + Baseline BMI Category + Baseline + Time\*Sex +Time\*Baseline BMI Category + Treatment\*Time + Time\*Baseline. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 48

  2. Mean Percentage of Participants Who Achieved Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline to Week 48

    Mean percentage of participants who achieved ≥5% body weight reduction was analysed by logistic regression model with multiple imputation. Model: Variable = Baseline + Treatment + Sex + Baseline BMI Category. Mean percentage of participants was calculated by combining percentage of participants achieving target at week 48 in imputed data sets using Rubin's rule.

    Time frame: Baseline to Week 48

  3. Mean Percentage of Participants Who Achieved ≥ 10% Body Weight Reduction From Baseline to Week 48

    Mean percentage of participants who achieved ≥10% body weight reduction was analysed by logistic regression model with multiple imputation. Model: Variable = Baseline + Treatment + Sex + Baseline BMI Category. Mean percentage of participants was calculated by combining percentage of participants achieving target at week 48 in imputed data sets using Rubin's rule.

    Time frame: Baseline to Week 48

  4. Change From Baseline in Body Mass Index (BMI) at Week 48

    LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment + Time + Sex + Baseline BMI Category + Baseline + Time\*Sex +Time\*Baseline BMI Category + Treatment\*Time + Time\*Baseline. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 48

  5. Pharmacokinetics (PK): Area Under the Curve (AUC) of Eloralintide at Steady State

    PK samples were analyzed using a population PK model approach to estimate AUC at steady state. Data presented are Geometric Mean with 90% prediction interval (PI).

    Time frame: Predose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 36; Post dose (2 to 6 hours after dosing) at Week 0, Week 24; Post dose (24 to 72 hours after dosing) at Week 12; random at Week 48

  6. PK: Maximum Concentration (Cmax) of Eloralintide at Steady State

    PK samples were analyzed using a population PK model approach to estimate Cmax at steady state. Data presented are Geometric Mean with 90% prediction interval (PI).

    Time frame: Predose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 36; Post dose (2 to 6 hours after dosing) at Week 0, Week 24; Post dose (24 to 72 hours after dosing) at Week 12; random at Week 48

07

Results

Posted Jun 24, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg Eloralintide
Started53282428542452
Completed38151921481946
Not completed151357656
Withdrew: Adverse event2201102
Withdrew: Lost to follow-up5323220
Withdrew: Physician decision1000000
Withdrew: Withdrawal by subject6723233
Withdrew: Other1110101

Outcome measures

PrimaryPercent Change From Baseline in Body Weight at Week 48

Least squares (LS) means were calculated using a mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Treatment + Time + Sex + Baseline BMI Category + Baseline + Time\*Sex +Time\*Baseline BMI Category + Treatment\*Time + Time\*Baseline. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight at Week 48
percent changePlacebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg Eloralintide
Percent Change From Baseline in Body Weight at Week 48-0.4 ± 0.91-9.4 ± 1.60-12.4 ± 1.30-17.6 ± 1.56-20.1 ± 1.31-19.9 ± 1.45-16.5 ± 1.18
SecondaryChange From Baseline in Body Weight at Week 48

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment + Time + Sex + Baseline BMI Category + Baseline + Time\*Sex +Time\*Baseline BMI Category + Treatment\*Time + Time\*Baseline. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Kilograms (Kg)
Change From Baseline in Body Weight at Week 48
Kilograms (Kg)Placebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg Eloralintide
Change From Baseline in Body Weight at Week 48-0.2 ± 1.01-10.2 ± 1.66-13.3 ± 1.37-18.7 ± 1.81-21.3 ± 1.41-21.0 ± 1.46-18.0 ± 1.37
SecondaryMean Percentage of Participants Who Achieved Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline to Week 48

Mean percentage of participants who achieved ≥5% body weight reduction was analysed by logistic regression model with multiple imputation. Model: Variable = Baseline + Treatment + Sex + Baseline BMI Category. Mean percentage of participants was calculated by combining percentage of participants achieving target at week 48 in imputed data sets using Rubin's rule.

Time frame:
Baseline to Week 48
Reported as:
Mean · percentage of participants
Mean Percentage of Participants Who Achieved Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline to Week 48
percentage of participantsPlacebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg Eloralintide
Mean Percentage of Participants Who Achieved Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline to Week 4831.21 ± 7.1971.55 ± 9.8187.12 ± 7.7584.99 ± 8.0492.72 ± 4.0797.50 ± 4.0090.80 ± 4.78
SecondaryMean Percentage of Participants Who Achieved ≥ 10% Body Weight Reduction From Baseline to Week 48

Mean percentage of participants who achieved ≥10% body weight reduction was analysed by logistic regression model with multiple imputation. Model: Variable = Baseline + Treatment + Sex + Baseline BMI Category. Mean percentage of participants was calculated by combining percentage of participants achieving target at week 48 in imputed data sets using Rubin's rule.

Time frame:
Baseline to Week 48
Reported as:
Mean · percentage of participants
Mean Percentage of Participants Who Achieved ≥ 10% Body Weight Reduction From Baseline to Week 48
percentage of participantsPlacebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg Eloralintide
Mean Percentage of Participants Who Achieved ≥ 10% Body Weight Reduction From Baseline to Week 4812.85 ± 5.3753.25 ± 10.7660.45 ± 11.0676.57 ± 9.2782.32 ± 5.5591.13 ± 6.3379.24 ± 6.17
SecondaryChange From Baseline in Body Mass Index (BMI) at Week 48

LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment + Time + Sex + Baseline BMI Category + Baseline + Time\*Sex +Time\*Baseline BMI Category + Treatment\*Time + Time\*Baseline. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kilogram per square metre (kg/m^2)
Change From Baseline in Body Mass Index (BMI) at Week 48
kilogram per square metre (kg/m^2)Placebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg Eloralintide
Change From Baseline in Body Mass Index (BMI) at Week 48-0.2 ± 0.37-3.7 ± 0.58-4.7 ± 0.50-6.7 ± 0.65-7.7 ± 0.50-7.8 ± 0.60-6.4 ± 0.47
SecondaryPharmacokinetics (PK): Area Under the Curve (AUC) of Eloralintide at Steady State

PK samples were analyzed using a population PK model approach to estimate AUC at steady state. Data presented are Geometric Mean with 90% prediction interval (PI).

Time frame:
Predose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 36; Post dose (2 to 6 hours after dosing) at Week 0, Week 24; Post dose (24 to 72 hours after dosing) at Week 12; random at Week 48
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Curve (AUC) of Eloralintide at Steady State
nanogram*hour per milliliter (ng*h/mL)1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide
Pharmacokinetics (PK): Area Under the Curve (AUC) of Eloralintide at Steady State47300 (NA to NA)148000 (NA to NA)306000 (NA to NA)468000 (NA to NA)
SecondaryPK: Maximum Concentration (Cmax) of Eloralintide at Steady State

PK samples were analyzed using a population PK model approach to estimate Cmax at steady state. Data presented are Geometric Mean with 90% prediction interval (PI).

Time frame:
Predose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 36; Post dose (2 to 6 hours after dosing) at Week 0, Week 24; Post dose (24 to 72 hours after dosing) at Week 12; random at Week 48
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Eloralintide at Steady State
nanogram per milliliter (ng/mL)1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide
PK: Maximum Concentration (Cmax) of Eloralintide at Steady State322 (NA to NA)1010 (NA to NA)2090 (NA to NA)3210 (NA to NA)

Adverse events

Collected over Baseline to end of safety follow-up (up to 58 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/53 (0%)3/53 (5.7%)25/53 (47.2%)
1 mg Eloralintide0/28 (0%)3/28 (10.7%)15/28 (53.6%)
3 mg Eloralintide0/24 (0%)1/24 (4.2%)12/24 (50%)
6 mg Eloralintide0/28 (0%)1/28 (3.6%)27/28 (96.4%)
9 mg Eloralintide0/54 (0%)3/54 (5.6%)40/54 (74.1%)
6/9 mg Eloralintide0/24 (0%)2/24 (8.3%)20/24 (83.3%)
3/6/9 mg Eloralintide0/52 (0%)1/52 (1.9%)34/52 (65.4%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlacebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg Eloralintide
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/401/210/190/210/430/190/41
Acute myocardial infarctionCardiac disorders0/530/281/240/280/541/240/52
Spondylitic myelopathyNervous system disorders0/530/280/240/280/541/240/52
LymphadenopathyBlood and lymphatic system disorders0/531/280/240/280/540/240/52
Atrial flutterCardiac disorders0/531/280/240/280/540/240/52
Multiple sclerosisNervous system disorders0/530/280/241/280/540/240/52
Suicidal ideationPsychiatric disorders0/531/280/240/280/540/240/52
Diverticulitis meckel'sCongenital, familial and genetic disorders0/530/280/240/280/540/241/52
Small intestinal obstructionGastrointestinal disorders0/530/280/240/280/540/241/52
MastoiditisInfections and infestations1/530/280/240/280/540/240/52
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPlacebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg Eloralintide
NauseaGastrointestinal disorders7/533/283/2418/2818/5413/2413/52
FatigueGeneral disorders6/530/283/248/2823/5411/2411/52
DiarrhoeaGastrointestinal disorders5/531/282/2410/286/543/249/52
VomitingGastrointestinal disorders0/530/280/247/286/544/241/52
ConstipationGastrointestinal disorders3/534/284/242/2813/544/244/52
Upper respiratory tract infectionInfections and infestations6/532/282/242/280/545/243/52
Benign prostatic hyperplasiaReproductive system and breast disorders2/131/70/50/70/110/50/11
Decreased appetiteMetabolism and nutrition disorders2/530/282/244/288/541/245/52
Covid-19Infections and infestations2/534/281/243/280/542/245/52
Prostate infectionInfections and infestations0/130/70/51/70/110/50/11

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg EloralintideTotal
Mean48.80 ± 12.3050.40 ± 13.9348.60 ± 12.1746.10 ± 14.5750.20 ± 12.3449.10 ± 10.9348.70 ± 12.8949.00 ± 12.65
Sex: Female, Male
Sex: Female, Male(Participants)Placebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg EloralintideTotal
Female40211921431941204
Male137571151159
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg EloralintideTotal
Hispanic or Latino103111061041
Not Hispanic or Latino43252327441842222
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg EloralintideTotal
American Indian or Alaska Native00001012
Asian01100013
Native Hawaiian or Other Pacific Islander10010013
Black or African American105431421048
White41211924392239205
More than one race10000001
Unknown or Not Reported01000001
Region of Enrollment
Region of Enrollment(Participants)Placebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg EloralintideTotal
United States53282428542452263
Body Weight
Body Weight(Kilograms (Kg))Placebo1 mg Eloralintide3 mg Eloralintide6 mg Eloralintide9 mg Eloralintide6/9 mg Eloralintide3/6/9 mg EloralintideTotal
Mean109.02 ± 21.96113.02 ± 34.96107.75 ± 18.97106.94 ± 18.15106.99 ± 17.17110.03 ± 24.55110.76 ± 24.18109.13 ± 22.75
08

Study locations

43 sites
  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
    Chandler, Arizona 85225, United States
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson
    Tucson, Arizona 85712, United States
  • NorCal Medical Research, Inc
    Greenbrae, California 94904, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Northeast Research Institute (NERI)
    Fleming Island, Florida 32003, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Charter Research - Winter Park
    Orlando, Florida 32803, United States
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
  • Pacific Diabetes & Endocrine Center
    Honolulu, Hawaii 96817, United States
  • Medical Research Partners
    Ammon, Idaho 83406, United States
  • Great Lakes Clinical Trials - Andersonville
    Chicago, Illinois 60640, United States
  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
  • NorthShore University Health System
    Skokie, Illinois 60077, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Knownwell
    Needham, Massachusetts 02492, United States
  • Lucida Clinical Trials
    New Bedford, Massachusetts 02740, United States
  • Headlands Research - Detroit
    Southfield, Michigan 48034, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
  • Velocity Clinical Research, Syracuse
    East Syracuse, New York 13057, United States
  • North Suffolk Neurology
    Port Jefferson Station, New York 11776, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Medication Management
    Greensboro, North Carolina 27405, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Lucas Research, Inc.
    New Bern, North Carolina 28562, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
  • IMA Clinical Research Austin
    Austin, Texas 78745, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75251, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Tekton Research - Fredericksburg Road
    San Antonio, Texas 78229, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • Spectrum Medical, Inc.
    Danville, Virginia 24541, United States
  • Central Washington Health Services Association d/b/a Confluence Health
    Wenatchee, Washington 98801, United States
09

References and documents

Publications

  • Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, Butler A, Kazda C, Mather KJ, Coskun T. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Dec 6;406(10520):2631-2643. doi: 10.1016/S0140-6736(25)02155-5. Epub 2025 Nov 6. PubMed 41207310 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06230523
Lead sponsor
Eli Lilly and Company
Responsible party
Sponsor
First posted
Jan 30, 2024
Start date
Feb 5, 2024
Primary completion
May 30, 2025
Completion
Aug 14, 2025
Results posted
Jun 24, 2026
Last update
Jun 24, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eloralintide

Other studies in this condition

Obesity →

Other studies from this sponsor

Eli Lilly and Company →

Start the discussion